Cornerstone Therapeutics has signed an agreement to acquire exclusive US marketing rights to Pertzye (pancrelipase) from Digestive Care (DCI).
Pertzye, the pancreatic enzyme product, is indicated for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).
DCI earlier marketed the Pertzye formulation under the trade name PANCRECARB MS-16.
Cornerstone chief executive officer Craig Collard said, "With net sales of PERT products reaching approximately $200 million in the CF category in 2012, we see significant opportunity for growth. Also, the addition of PERTZYE complements Cornerstone's launch of the CF drug BETHKIS (tobramycin inhalation solution) later this year."
DCI president and chief scientific officer Dr. Tibor Sipos said, "We are pleased to partner with Cornerstone and are confident that their CF-focused marketing efforts will enhance patient accessibility to PERTZYE and provide support for educational programs."
